Search tips
Search criteria 


Logo of brheartjLink to Publisher's site
Br Heart J. 1978 October; 40(10): 1069–1118.
PMCID: PMC483536

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (5.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Barnett D, Craig JG, Robinson DS, Rogers MP. Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br J Clin Pharmacol. 1977 Aug;4(4):455–458. [PubMed]
  • Barrett AM, Thorp JM. Studies on the mode of action of clofibrate: effects on hormone-induced changes in plasma free fatty acids, cholesterol, phospholipids and total esterified fatty acids in rats and dogs. Br J Pharmacol Chemother. 1968 Feb;32(2):381–391. [PubMed]
  • Berkowitz D. Long-term treatment of hyperlipidemic patients with clofibrate. JAMA. 1971 Nov 15;218(7):1002–1005. [PubMed]
  • BLACKBURN H, KEYS A, SIMONSON E, RAUTAHARJU P, PUNSAR S. The electrocardiogram in population studies. A classification system. Circulation. 1960 Jun;21:1160–1175. [PubMed]
  • Brown DF, Kinch SH, Doyle JT. Serum triglycerides in health and in ischemic heart disease. N Engl J Med. 1965 Oct 28;273(18):947–952. [PubMed]
  • Carlson LA, Böttiger LE. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study. Lancet. 1972 Apr 22;1(7756):865–868. [PubMed]
  • Cooper J, Geizerova H, Oliver MF. Letter: Clofibrate and gallstones. Lancet. 1975 May 10;1(7915):1083–1083. [PubMed]
  • Dewar HA, Oliver MF. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. Br Med J. 1971 Dec 25;4(5790):784–786. [PMC free article] [PubMed]
  • Einarsson K, Hellström K, Leijd B. Bile acid kinetics and steroid balance during nicotinic acid therapy in patients with hyperlipoproteinemia types II and IV. J Lab Clin Med. 1977 Oct;90(4):613–622. [PubMed]
  • Enger SC, Johnsen V, Samuelsen A, Laws EA. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease. Acta Med Scand. 1977;201(6):563–566. [PubMed]
  • Feinstein AR. Clinical biostatistics. 18. The clofibrate trials: another dispute about contratrophic therapy. Clin Pharmacol Ther. 1972 Nov-Dec;13(6):953–968. [PubMed]
  • Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. 1967 Feb 2;276(5):273–concl. [PubMed]
  • Grundy SM, Ahrens EH, Jr, Salen G, Schreibman PH, Nestel PJ. Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res. 1972 Jul;13(4):531–551. [PubMed]
  • Halperin M, Cornfield J, Mitchell SC. Effect of diet on coronary-heart-disease mortality. Lancet. 1973 Aug 25;2(7826):438–439. [PubMed]
  • Heady JA. A cooperative trial on the primary prevention of ischaemic heart disease using clofibrate: design, methods, and progress. Bull World Health Organ. 1973;48(2):243–256. [PubMed]
  • Hill MJ, Drasar BS, Williams RE, Meade TW, Cox AG, Simpson JE, Morson BC. Faecal bile-acids and clostridia in patients with cancer of the large bowel. Lancet. 1975 Mar 8;1(7906):535–539. [PubMed]
  • Kannel WB, Doyle JT, McNamara PM, Quickenton P, Gordon T. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation. 1975 Apr;51(4):606–613. [PubMed]
  • Keys A, Aravanis C, Blackburn H, Van Buchem FS, Buzina R, Djordjevic BS, Fidanza F, Karvonen MJ, Menotti A, Puddu V, et al. Probability of middle-aged men developing coronary heart disease in five years. Circulation. 1972 Apr;45(4):815–828. [PubMed]
  • Krasno LR, Kidera GJ. Clofibrate in coronary heart disease. Effect on morbidity and mortality. JAMA. 1972 Feb 14;219(7):845–851. [PubMed]
  • Lithell H, Boberg J, Hedstrand H, Hellsing K, Ljunghall S, Vessby B. Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen. Eur J Clin Pharmacol. 1977 Aug 17;12(1):51–57. [PubMed]
  • Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed]
  • Medalie JH, Kahn HA, Neufeld HN, Riss E, Goldbourt U, Perlstein T, Oron D. Myocardial infarction over a five-year period. I. Prevalence, incidence and mortality experience. J Chronic Dis. 1973 Feb;26(2):63–84. [PubMed]
  • Miettinen M, Turpeinen O, Karvonen MJ, Elosuo R, Paavilainen E. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women. Lancet. 1972 Oct 21;2(7782):835–838. [PubMed]
  • OLIVER MF. Reduction of serum-lipid and uric-acid levels by an orally active androsterone. Lancet. 1962 Jun 23;1(7243):1321–1323. [PubMed]
  • Pertsemlidis D, Panveliwalla D, Ahrens EH., Jr Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology. 1974 Apr;66(4):565–573. [PubMed]
  • Sturdevant RA, Pearce ML, Dayton S. Increased prevalence of cholelithiasis in men ingesting a serum-cholesterol-lowering diet. N Engl J Med. 1973 Jan 4;288(1):24–27. [PubMed]
  • THROP JM. Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate. Lancet. 1962 Jun 23;1(7243):1323–1326. [PubMed]
  • THORP JM, WARING WS. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature. 1962 Jun 9;194:948–949. [PubMed]
  • Walker SH, Duncan DB. Estimation of the probability of an event as a function of several independent variables. Biometrika. 1967 Jun;54(1):167–179. [PubMed]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group